CN110256416B - 组蛋白去乙酰化酶抑制剂及其制备方法与用途 - Google Patents
组蛋白去乙酰化酶抑制剂及其制备方法与用途 Download PDFInfo
- Publication number
- CN110256416B CN110256416B CN201910393161.4A CN201910393161A CN110256416B CN 110256416 B CN110256416 B CN 110256416B CN 201910393161 A CN201910393161 A CN 201910393161A CN 110256416 B CN110256416 B CN 110256416B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- formula
- alkyl group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003276 histone deacetylase inhibitor Substances 0.000 title claims abstract description 10
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 29
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 230000002159 abnormal effect Effects 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 102100021454 Histone deacetylase 4 Human genes 0.000 claims description 9
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 4
- 102100021453 Histone deacetylase 5 Human genes 0.000 claims description 3
- 102100038720 Histone deacetylase 9 Human genes 0.000 claims description 3
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 101001032113 Homo sapiens Histone deacetylase 7 Proteins 0.000 claims description 2
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000011535 reaction buffer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 102000006947 Histones Human genes 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 230000006195 histone acetylation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 2
- KBNWGVBBEPQFIZ-UHFFFAOYSA-N 2,3-dihydro-1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NCCC2=C1 KBNWGVBBEPQFIZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- -1 hydrofluoric Chemical compound 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- UFFVNATYYXBMGO-INIZCTEOSA-N tert-butyl n-[(2s)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxo-6-[(2,2,2-trifluoroacetyl)amino]hexan-2-yl]carbamate Chemical compound C1=C(NC(=O)[C@H](CCCCNC(=O)C(F)(F)F)NC(=O)OC(C)(C)C)C=CC2=C1OC(=O)C=C2C UFFVNATYYXBMGO-INIZCTEOSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种组蛋白去乙酰化酶抑制剂,本发明公开了式I所示的化合物及其立体异构体。本发明公开的式I所示的新化合物,表现出了良好的去乙酰化酶抑制活性,为临床治疗与组蛋白去乙酰化酶活性异常相关的疾病提供了一种新的药用可能。
Description
技术领域
本发明涉及一种组蛋白去乙酰化酶抑制剂及其制备方法与用途。
背景技术
在机体中控制细胞生长的基因失活是肿瘤发生的一个标志。引起基因失活的外遗传机制主要包括DNA甲基化,组蛋白乙酰化和染色质高级结构中其他成分的修饰,这些修饰改变染色质构型,导致基因转录调节发生变化,基因转录的失调引起细胞增殖失常,从而导致肿瘤产生。
组蛋白乙酰化对于真核细胞的转录调控起核心作用。组蛋白乙酰化作用受一对功能相互拮抗的蛋白酶组蛋白乙酰化转移酶(HATs)和组蛋白去乙酰化酶(HDACs)调控。在正常细胞中,这一对酶处于动态平衡状态。一般情况下,组蛋白乙酰化水平增强与基因转录活性增强有关,而乙酰化水平过低与基因表达抑制有关(Forsberg EC et al.Bioessays,2001,23(9):820-830)。研究发现,HDAC过度表达并被转录因子募集,导致特定基因的不正常抑制,从而导致肿瘤和其他疾病;而抑制HDAC的活性将引起许多癌细胞的生长抑制和凋亡(Somech R et al.Cancer Treat Rev,2004,30(5):461-472)。因此,HDAC已成为目前抗肿瘤药物研发领域最新和最热门的靶标。
在人类中,已经鉴别出18种HDAC并且可分为四类。其中11种HDAC利用锌作为辅助因子,可分为四类:类别I(HDAC 1、2、3和8)、类别IIa(HDAC 4、5、7和9)、类别IIb(HDAC 6和10)、类别IV(HDAC 11);另外7种HDAC为类别III,需要NAD+作为额外辅助因子(Bolden etal.Nat.Rev.Drug,2006,5(9):769-784)。其中IIa类HDACs可以通过胞浆胞核穿梭调控糖脂代谢相关基因的表达,如糖异生相关葡萄糖6磷酸酶、磷酸烯醇式丙酮酸羧激酶、甘油三酯脂肪酶、葡萄糖转运蛋白等。近年来发现,IIa类HDACs是与临床相关的分子靶标,这类去乙酰化酶在调节肌肉分化以及失活HDAC5和HDAC9基因导致心肌细胞肥大中扮演重要角色。另外IIa类组蛋白去乙酰化酶与临床心血管疾病、呼吸系统疾病和骨软骨疾病的发生、肿瘤进展以及药学研究等密切相关。
HDAC抑制剂作用机制是通过抑制HDAC,阻断由于HDAC募集功能紊乱而导致的基因表达受抑,通过改变组蛋白的乙酰化程度来改变染色质结构,从而调控基因表达治疗癌症。它通过诱导肿瘤细胞的生长停滞、分化或凋亡对治疗血液系统肿瘤和实体瘤疗效显著。HDAC抑制剂具有肿瘤特异性,对增殖和静止的变异细胞均有细胞毒作用,而正常细胞对它有10倍以上的耐受,不会引起正常细胞的生长停滞和凋亡。
目前已研发的HDAC抑制剂,在抗癌活性、毒副作用、亚型选择性等方面也存在一定的问题。因此,开发一种具有组蛋白去乙酰化酶抑制活性的新化合物具有十分重要的社会和经济意义。
发明内容
为了解决上述问题,本发明提供了一种具有组蛋白去乙酰化酶抑制活性的化合物。
本发明提供的式I所示的化合物或其立体异构体:
其中,
表示双键或单键;
X选自-C(O)-、-S(O)2-;
Y选自CR2、N;
A环选自5~10元芳环、5~10元芳杂环;其中芳环、芳杂环可进一步被m个R3取代;
R1选自卤素、-NR4R5、-NR4C(O)R5、-NR4C(O)NR5R6、-NR4S(O)R5、-NR4S(O)2R5、-NR4S(O)NR5R6、-NR4S(O)2NR5R6、-OR4、-OC(O)R4、-OC(O)NR4R5;
m为1、2、3、4或5;
R2、R3分别独自选自氢、卤素、C1~6烷基、C2~6烯基、C2~6炔基、C1~6卤素烷基、-CN、-NO2、-ORa、-NRaRb;
R4、R5、R6分别独自选自氢、C1~6烷基、C2~6烯基、C2~6炔基、3~10元环烷基、3~10元杂环烷基;其中烷基、烯基、炔基、环烷基、杂环烷基可进一步被n个Rc取代;
或者,R4可与R5或R6相连形成3~10元杂环烷基;其中杂环烷基可进一步被n个Rc取代;
Ra、Rb分别独自选自氢、C1~6烷基、C2~6烯基、C2~6炔基;
n为1、2、3、4或5;
Rc分别独自选自卤素、C1~6烷基、C2~6烯基、C2~6炔基、3~10元环烷基、3~10元杂环烷基、-CN、-NO2、-ORa、-NRaRb。
优选的,
A环选自5~6元芳环、5~6元芳杂环;
X选自-S(O)2-;
R1选自卤素、-NR4R5、-NR4C(O)R5、-NR4S(O)2R5、OR4、-OC(O)R4;
m为1、2、3或4;
n为1、2、3或4。
在一些实施方案中,式I所示的化合物可进一步用式IIa表示:
其中,
R4、R5分别独自选自氢、C1~6烷基、C2~6烯基、C2~6炔基;其中烷基、烯基、炔基可进一步被n个Rc取代;
或者,R4可与R5相连形成3~10元杂环烷基;
n为1、2、3或4;
Rc分别独自选自3~6元环烷基、3~6元杂环烷基、-ORa、-NRaRb。
在一些实施方案中,式IIa所示的化合物可具体表示为:
在一些实施方案中,式I所示的化合物可进一步用式IIb表示:
其中,
R4选自氢、C1~6烷基、C2~6烯基、C2~6炔基;其中烷基、烯基、炔基可进一步被n个Rc取代;
n为1、2、3或4;
Rc分别独自选自3~6元环烷基、3~6元杂环烷基、-ORa、-NRaRb。
在一些实施方案中,式IIb所示的化合物可具体表示为:
在一些实施方案中,式I所示的化合物可进一步用式IIc表示:
其中,R1优选为卤素。
在一些实施方案中,式IIc所示的化合物可具体表示为:
本发明的另一目的在于上述化合物或其立体异构体,在制备HDAC抑制剂类药物中的用途。
所述HDAC抑制剂类药物是治疗由HDAC活性异常所导致的疾病的药物。特别是由HDAC4、HDAC5、HDAC7或HDAC9活性异常所导致的疾病的药物。
进一步,所述疾病是细胞增殖疾病、自身免疫疾病、炎症、神经变性疾病或病毒性疾病中的任意一种或多种。
更进一步,所述疾病为癌症。
一种抑制组蛋白去乙酰化酶活性的药物组合物,它是以上述化合物或其晶型、药学上可接受的盐、水合物或溶剂合物为活性成分,加上药学上常用的辅料或辅助性成分制备得到的制剂。
本发明中提供的化合物和衍生物可以根据IUPAC(国际纯粹与应用化学联合会)或CAS(化学文摘服务社,Columbus,OH)命名系统命名。
关于本发明的使用术语的定义:除非另有说明,本文中基团或者术语提供的初始定义适用于整篇说明书的该基团或者术语;对于本文没有具体定义的术语,应该根据公开内容和上下文,给出本领域技术人员能够给予它们的含义。
“取代”是指分子中的氢原子被其它不同的原子或分子所替换。
碳氢基团中碳原子含量的最小值和最大值通过前缀表示,例如,前缀Ca~b烷基表明任何含“a”至“b”个碳原子的烷基。因此,例如,“C1~4烷基”是指包含1~4个碳原子的烷基。
“卤素”为氟、氯、溴或碘。
“卤素烷基”指烷基中的氢原子可被一个或多个卤素原子取代。例如C1~4卤素烷基指氢原子被一个或多个卤素原子取代的包含1~4个碳原子的烷基。
“杂环”、“杂环烷基”指包含至少一个杂原子的饱和环或非芳香性的不饱和环;其中杂原子指氮原子、氧原子、硫原子;
“芳杂环”指包含至少一个杂原子的芳香性不饱和环;其中杂原子指氮原子、氧原子、硫原子;
“立体异构体”包括对映异构体和非对映异构体;
术语“药学上可接受的”是指某载体、运载物、稀释剂、辅料,和/或所形成的盐通常在化学上或物理上与构成某药物剂型的其它成分相兼容,并在生理上与受体相兼容。
术语“盐”和“可药用的盐”是指上述化合物或其立体异构体,与无机和/或有机酸和碱形成的酸式和/或碱式盐,也包括两性离子盐(内盐),还包括季铵盐,例如烷基铵盐。这些盐可以是在化合物的最后分离和纯化中直接得到。也可以是通过将上述化合物,或其立体异构体,与一定数量的酸或碱适当(例如等当量)进行混合而得到。这些盐可能在溶液中形成沉淀而以过滤方法收集,或在溶剂蒸发后回收而得到,或在水介质中反应后冷冻干燥制得。本发明中所述盐可以是化合物的盐酸盐、硫酸盐、枸橼酸盐、苯磺酸盐、氢溴酸盐、氢氟酸盐、磷酸盐、乙酸盐、丙酸盐、丁二酸盐、草酸盐、苹果酸盐、琥珀酸盐、富马酸盐、马来酸盐、酒石酸盐或三氟乙酸盐。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
本发明具体实施方式中使用的原料、设备均为已知产品,通过购买市售产品获得。
化合物的结构是通过核磁共振(NMR)或(和)质谱(MS)来确定的。NMR位移(δ)以10-6(ppm)的的单位给出。NMR的测定是用(Bruker AvanceIII 400和Bruker Avance 300)核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d6),氘代氯仿(CDCl3),氘代甲醇(CD3OD),内标为四甲基硅烷(TMS)。
LC-MS的测定用岛津液质联用仪(Shimadzu LC-MS 2020(ESI))。
HPLC的测定使用岛津高压液相色谱仪(Shimadzu LC-20A)。
反相制备色谱(pre-HPLC)使用Gilson GX-281反相制备色谱仪,通用制备方法为:流动相A:含0.05%三氟乙酸的纯水;流动相B:乙腈;梯度:流动相B含量5%-95%)。
薄层层析硅胶板用烟台黄海HSGF254或青岛GF254硅胶板,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm。
柱层析一般使用烟台黄海硅胶200~300目硅胶为载体。
本发明所用原料主要购买于百灵威化学、韶远化学科技有限公司、Alfa Aesar、江苏艾康生物医药研发有限公司和梯希爱(上海)化成工业发展有限公司等供应商。
室温为最适宜的反应温度,一般为20℃~30℃。
实施例中无特殊说明,溶液是指水溶液。
实施例中无特殊说明,反应的温度为室温。
过夜为12±1h。
原料和试剂简称:
Pd2(dba)3:三(二亚苄基丙酮)二钯
BINAP:1,1'-联萘-2,2'-双二苯膦
DMSO:二甲基亚砜
Pd(PPh3)4:四(三苯基膦)钯
POCl3:三氯氧磷
PE:石油醚
EA:乙酸乙酯
TEA:三乙胺
MeOH:甲醇
EtOH:乙醇
DCM:二氯甲烷
实施例1、本发明化合物的制备。
步骤1:中间体1a的制备
将5-氰基-吲哚啉(1.00g,6.94mmol)和TEA(2.88mL,20.8mmol)溶于DCM(30mL)中,加入3-溴-苯磺酰氯(1.95g,7.63mmol)并于室温下搅拌过夜。加水淬灭反应,分出DCM层,用DCM萃取水层两次,合并DCM层干燥后旋干,得淡黄色固体中间体1a(2.26g,收率:90%)。
步骤2:中间体1b的制备
中间体1a(680mg,1.87mmol),N,N-二甲基乙二胺(330mg,3.74mmol),Pd2(dba)3(171mg,187.21umol),BINAP(233mg,374.42umol)和t-BuONa(539mg,5.62mmol)依次加入甲苯(15mL)中,氮气保护,加热至100℃下搅拌过夜,加水洗,有机层干燥后旋干,柱层析纯化(DCM:MeOH=50:1),得到棕色油状物中间体1b(450mg,收率:65%)。
步骤3:中间体1c的制备
将中间体1b(250mg,674.82umol)加入乙醇(5mL),再加入盐酸羟胺(469mg,6.75mmol)和三乙胺(683mg,6.75mmol,941.22uL),升温至60℃搅拌2h,减压旋去溶剂,残余物(中间体1c)直接用于下一步反应。
步骤4:实施例1化合物的制备
中间体1c(279mg,691umol)悬浮于吡啶(5mL)中,室温下滴入三氟乙酸酐(726mg,3.46mmol),并于室温下搅拌3h。将反应液倒于水中,乙酸乙酯提取3次,合并有机层,旋干后经pre-HPLC纯化,得到白色固体实施例1化合物(148mg,收率:39%)。
MS(ESI)m/z=482[M+H]+
1H NMR(400MHz,DMSO-d6)δ10.75(s,1H),7.90(dd,J=8.4,2.0Hz,1H),7.86(d,J=2.0Hz,1H),7.65(dd,J=8.4,2.4Hz,1H),7.32(t,J=8.0Hz,1H),7.11–7.03(m,2H),6.96–6.88(m,1H),3.99(t,J=8.4Hz,2H),3.46(t,J=6.4Hz,2H),3.19(t,J=6.4Hz,2H),3.11(t,J=8.4Hz,2H),2.77(s,3H),2.75(s,3H)。
实施例2、本发明化合物的制备
按照实施例1中步骤1至步骤4的合成方法,并将步骤1中的3-溴-苯磺酰氯换成4-溴-苯磺酰氯,得到实施例2化合物(收率:25%)。
MS(ESI)m/z=482[M+H]+
1H NMR(401MHz,DMSO-d6)δ7.90(dd,J=8.4,2.0Hz,1H),7.83(d,J=2.0Hz,1H),7.66–7.57(m,3H),6.72–6.65(m,2H),3.91(t,J=8.4Hz,2H),3.44(q,J=6.4Hz,2H),3.19(t,J=6.4Hz,2H),3.06(t,J=8.4Hz,2H),2.79(s,6H)。
实施例3、本发明化合物的制备
按照实施例1中步骤1至步骤4的合成方法,并将步骤1中的3-溴-苯磺酰氯换成4-溴-苯磺酰氯,将步骤2中的N,N-二甲基乙二胺换成乙醇胺,得到实施例3化合物(收率:4.6%)。
MS(ESI)m/z=455[M+H]+
1H NMR(400MHz,DMSO-d6)δ8.04–7.98(m,2H),7.95(dd,J=8.4,2.0Hz,1H),7.88(d,J=1.6Hz,1H),7.70–7.62(m,3H),4.07(t,J=8.4Hz,2H),3.88(t,J=5.2Hz,2H)3.10–3.05(m,4H)。
实施例4、本发明化合物的制备。
按照实施例1中步骤3至步骤4的合成方法,并将步骤3中的中间体1c换成中间体1a,得到实施例4化合物(收率:35%)。
MS(ESI)m/z=475[M+H]+
1H NMR(400MHz,DMSO-d6)δ8.04(t,J=2.0Hz,1H),7.99–7.85(m,4H),7.70(d,J=8.4Hz,1H),7.58(t,J=8.0Hz,1H),4.06(t,J=8.4Hz,2H),3.11(t,J=8.4Hz,2H)。
实施例5、本发明化合物的制备。
按照实施例1中步骤1至步骤4的合成方法,并将步骤1中的3-溴-苯磺酰氯换成4-溴-苯磺酰氯,将步骤2中的N,N-二甲基乙二胺换成哌啶,得到实施例5化合物(收率:5.8%)。
MS(ESI)m/z=479[M+H]+
1H NMR(400MHz,DMSO-d6)δ7.92(dd,J=8.4,2.0Hz,1H),7.84(d,J=2.0Hz,1H),7.69–7.60(m,3H),7.00–6.94(m,2H),3.92(t,J=8.4Hz,2H),3.80(t,J=8.4Hz,2H),3.30(t,J=5.2Hz,4H),1.55–1.51(m,6H)。
实施例6、本发明化合物的制备
步骤1:中间体6a的制备
将N,N-二甲基-N-[(2-苯氧基)乙基]胺(1.65g,10.00mmol)溶于二氯甲烷(10mL)中,冰浴下缓慢滴加氯磺酸(2.5mL),升至室温搅拌3小时。将体系倾入到冰中,加入二氯甲烷(50mL),分离有机层,无水硫酸钠干燥,减压浓缩后得粗品中间体6a,直接用于下一步反应。
步骤2:中间体6b的制备
将5-氰基-吲哚啉(0.14g,1.00mmol)加入到二氯甲烷(6mL)中,依次加入吡啶(0.24g,3.00mmol)和中间体6a(0.27g,1.00mmol),加毕后于室温下搅拌1小时。减压浓缩后粗品中间体6b直接用于下一步反应。
步骤3:中间体6c的制备
按照实施例1中步骤3的合成方法,并将步骤3中的中间体1b换成中间体6b,得到中间体6c。
步骤4:实施例6化合物的制备
按照实施例1中步骤4的合成方法,并将步骤4中的中间体1c换成中间体6c,得到实施例6化合物(收率:43%)。
MS(ESI)m/z=483[M+H]+
1H NMR(400MHz,DMSO-d6)δ7.93(dd,J=8.4,2.0Hz,1H),7.87–7.79(m,3H),7.68(d,J=8.4Hz,1H),7.15–7.09(m,2H),4.11(t,J=5.6Hz,2H),3.97(t,J=8.4Hz,2H),3.08(t,J=8.4Hz,2H),2.61(t,J=5.6Hz,2H),2.19(s,6H)。
为了说明本发明的有益效果,本发明提供以下试验例:
试验例1 HDACIIa家族细胞水平酶活性检测方法
采用荧光方法检测化合物对HDACIIa家族细胞水平酶活性的抑制能力。
1640培养基配制:0.5%血清,0.5%DMSO,1640基础培养基,混匀。稀释受试化合物至所需终浓度的4倍,取12.5μL化合物至96孔检测板中,在阳性对照孔和阴性对照孔中,分别加入12.5μL 1640培养基。稀释底物至所需终浓度的4倍,取12.5μL底物至96孔检测板中。离心收集细胞,用1640培养基悬浮细胞并计数,接种细胞25μL,密度为100000个/孔至96孔检测板中,阴性对照孔中加入25μL 1640培养基,混匀。置细胞培养箱中培养3小时。在各反应孔中加入50μL胰酶终止液(2%Triton X-100,50μM TSA,胰蛋白酶溶液),混匀,室温避光孵育1小时,反应结束后,酶标仪读取96孔板中的荧光信号值(Ex:355nm,Em:460nm)。计算各浓度剩余活力百分比,公式为:剩余活力(%)=100*(化合物组荧光值-空白对照荧光值)/(阳性对照荧光值-空白对照荧光值),之后用GraphPad 5.0拟合剂效曲线计算EC50值。
试验例2 HDAC4酶学筛选试验
采用荧光方法检测化合物对HDAC4酶活性的抑制能力。
配制酶反应缓冲液,其中Tris 15mM,EDTA 0.25mM,NaCl 250mM,10%(v/v)甘油,用盐酸调节pH至8.1。
用DMSO稀释受试化合物至所需终浓度的1000倍,混匀后吸取2.5μl加入247.5μl酶反应缓冲液液中,充分混匀。吸取2.5μl酶反应缓冲液配制的化合物加入384孔黑板中,阳性对照孔和阴性对照孔分别加入2.5μl含1%DMSO的酶反应缓冲液。用酶反应缓冲液稀释HDAC4蛋白至1.2nM,除空白对照组外其余各孔加入2.5μl稀释好的HDAC4蛋白,空白对照组加入2.5μl酶反应缓冲液,384孔板1200rpm/min离心1min,使化合物和HDAC4室温预孵育10min,之后每孔加入10μl酶反应缓冲液。用酶反应缓冲液配制Boc-Lys(Tfa)-AMC浓度为25μM的底物溶液,于反应各孔中加入10μl,反应板1200rpm/min离心1min,37℃孵育30分钟。用胰酶配制SAHA浓度为2mM的混合终止液,HDAC4酶反应结束后于反应各孔中加入25μl SAHA胰酶的混合终止液,反应板1200rpm/min离心1min,室温孵育50分钟,反应结束后,酶标仪读取384孔板中的荧光信号值(Ex:355nm,Em:460nm)。计算各浓度剩余活力百分比,公式如下:剩余活力(%)=100*(荧光值化合物组-荧光值空白对照)/(荧光值阳性对照-荧光值空白对照)。之后用GraphPad5.0拟合剂效曲线计算IC50值。
试验例3细胞增殖抑制试验
采用CCK8方法检测化合物对细胞增殖的抑制能力。
细胞以每孔3000个细胞的密度接种到96孔细胞培养板中,37℃,5%二氧化碳培养箱过夜。化合物先使用DMSO梯度稀释,再用培养基配制成4×溶液,最后96孔细胞培养板中先加入150μl新鲜培养基后再加入50μl 4×化合物,37℃,5%二氧化碳培养箱培养72h。检测前配制cck-8检测液,取无血清培养基加入10%CCK-8检测液,混合均匀;弃掉96孔板中旧培养基,加入100μl CCK-8工作液,未铺细胞的孔也加入100μl CCK-8工作液为空白对照,37℃孵育1h,使用酶标仪读取450nm吸光值。计算remaining activity%:(各个浓度组吸光值-空白孔吸光值)/(不处理组吸光值-空白孔吸光值)*100%。根据各个化合物的remaining activity%使用Graphpad软件计算IC50。
试验例4乙酰化微管蛋白高内涵分析试验
采用高内涵分析方法检测化合物对微管蛋白乙酰化水平的影响。
HCT116细胞按照每孔5000个细胞的密度接种到96孔透明底黑板(Corning,货号3340)中,于37℃,5%CO2培养箱中培养过夜后更换新培养基,每孔50ul。化合物分别使用DMSO逐级稀释成不同浓度后使用培养基配制成2x终浓度的工作液(阴性对照组使用等体积DMSO替代),取50ul化合物工作液加入到96孔板中,稀释成1x终浓度,于37℃,5%CO2培养箱中培养6小时。细胞在化合物处理6小时后,使用4%多聚甲醛固定,每孔200ul,室温孵育15分钟。细胞固定后使用0.1%(v/v)TritonX-100通透细胞,每孔200ul,室温孵育15分钟。细胞使用1%封闭试剂封闭,每孔100ul,于振荡器上300rpm,孵育30分钟。封闭后每孔加入50ul使用1%(w/v)封闭试剂稀释后的乙酰化微管蛋白抗体(Sigma-Aldrich,货号:T6793,稀释比例为1:2000),于4℃冰箱中孵育过夜。抗体孵育后使用0.05%(v/v)PBST洗板,每孔200ul,重复4次。使用1%(w/v)封闭试剂稀释羊抗鼠荧光二抗(Invitrogen,货号:F-2761)和DAPI抗体(Thermofisher,货号:62247)(羊抗鼠荧光二抗稀释比例为1:500,DAPI的稀释比例为1:2000),每孔加入50ul稀释后的二抗,室温避光,于振荡器上300rpm孵育120分钟。再次使用0.05%(v/v)PBST洗板,每孔200ul,重复4次。使用高内涵成像分析系统(GE,InCell Analyzer,型号:2200)获取数据,每孔扫描9个视野,FITC通道曝光时间设置为0.01s,DAPI通道曝光时间设置为0.02s。使用In cell analyzer workstation软件分析数据,获得每孔细胞灰度值和背景值。使用Excel对获得的数据进行后续的处理,首先将每孔细胞灰度值减去背景灰度值获得标准化后的细胞灰度值,再将各个浓度处理后获得的标准化细胞灰度值分别除以阴性对照(DMSO处理)的标准化细胞灰度值获得不同化合物处理之后乙酰化微管蛋白相对于阴性对照的倍数变化,并在GraphPad Prism软件中拟合和计算相对于log浓度的EC50。
试验例5乙酰化组蛋白H3高内涵分析试验
采用高内涵分析方法检测化合物对组蛋白H3乙酰化水平的影响。
HCT116细胞按照每孔5000个细胞的密度接种到96孔透明底黑板(Corning,货号3340)中,于37℃,5%CO2培养箱中培养过夜后更换新培养基,每孔50ul。化合物分别使用DMSO逐级稀释成不同浓度后使用培养基配制成2x终浓度的工作液(阴性对照组使用等体积DMSO替代),取50ul化合物工作液加入到96孔板中,稀释成1x终浓度,于37℃,5%CO2培养箱中培养24小时。细胞在化合物处理24小时后,使用预冷的无水甲醇固定细胞,每孔200ul,室温孵育15分钟。细胞固定后使用0.1%(v/v)TritonX-100通透细胞,每孔200ul,室温孵育15分钟。细胞使用1%封闭试剂封闭,每孔100ul,于振荡器上300rpm,孵育30分钟。封闭后每孔加入50ul使用1%(w/v)封闭试剂稀释后的乙酰化组蛋白H3抗体(Abcam,货号:ab47915,稀释比例为1:1000),于4℃冰箱中孵育过夜。抗体孵育后使用0.05%(v/v)PBST洗板,每孔200ul,重复4次。使用1%(w/v)封闭试剂稀释羊抗兔荧光二抗(Invitrogen,货号:A11034)和DAPI抗体(Thermofisher,货号:62247)(羊抗兔荧光二抗稀释比例为1:500,DAPI的稀释比例为1:2000),每孔加入50ul稀释后的二抗,室温避光,于振荡器上300rpm孵育120分钟。再次使用0.05%(v/v)PBST洗板,每孔200ul,重复4次。使用高内涵成像分析系统(GE,InCell Analyzer,型号:2200)获取数据,每孔扫描9个视野,FITC通道曝光时间设置为0.01s,DAPI通道曝光时间设置为0.02s。使用In cell analyzer workstation软件分析数据,获得每孔细胞灰度值和背景值。使用Excel对获得的数据进行后续的处理,首先将每孔细胞灰度值减去背景灰度值获得标准化后的细胞灰度值,再将各个浓度处理后获得的标准化细胞灰度值分别除以阴性对照(DMSO处理)的标准化细胞灰度值获得不同化合物处理之后乙酰化微管蛋白相对于阴性对照的倍数变化,并在GraphPad Prism软件中拟合和计算相对于log浓度的EC50。
本发明化合物HDAC4酶学筛选试验、HDACIIa家族细胞水平酶活性检测结果如下:
实施例 | HDAC4IC50(nM) | Cellular IIa IC50(nM) |
1 | 373.1 | 9051 |
2 | 221.7 | 2231 |
3 | 1811 | 4337 |
4 | 2715 | >10000 |
5 | 1701 | >10000 |
6 | 350 | 3621 |
综上所述,本发明公开的式I所示的新化合物,表现出了良好的去乙酰化酶抑制活性,为临床治疗与组蛋白去乙酰化酶活性异常相关的疾病提供了一种新的药用可能。
Claims (13)
1.式I所示的化合物:
其中,
表示单键;
X选自-S(O)2-;
Y选自CR2;
A环选自6元芳环;
R1选自卤素、-NR4R5、-OR4;
m为1、2、3、4或5;
R2选自氢;
R4、R5分别独自选自氢、C1~6烷基;其中烷基可进一步被n个Rc取代;
或者,R4可与R5相连形成3~10元杂环烷基;其中杂环烷基可进一步被n个Rc取代;n为1、2、3、4或5;
Ra、Rb分别独自选自氢、C1~6烷基;
Rc分别独自选自-ORa、-NRaRb。
2.根据权利要求1所述的化合物,其特征在于:式I所示的化合物用式IIa表示:
其中,
R4、R5分别独自选自氢、C1~6烷基;其中烷基可进一步被n个Rc取代;
或者,R4可与R5相连形成3~10元杂环烷基;
n为1、2、3或4;
Rc分别独自选自-ORa、-NRaRb。
3.根据权利要求2所述的化合物,其特征在于:所示化合物为:
4.根据权利要求1所述的化合物,其特征在于:式I所示的化合物用式IIb表示:
其中,
R4选自氢、C1~6烷基;其中烷基可进一步被n个Rc取代;
n为1、2、3或4;
Rc分别独自选自-ORa、-NRaRb。
5.根据权利要求4所述的化合物,其特征在于:所示化合物为:
6.根据权利要求1所述的化合物,其特征在于:式I所示的化合物用式IIc表示:
其中,
R1为卤素。
7.根据权利要求6所述的化合物,其特征在于:所示化合物为:
8.权利要求1~7任一项所述的化合物在制备HDAC抑制剂类药物中的用途。
9.根据权利要求8所述的用途,其特征在于:所述HDAC抑制剂类药物为由HDAC活性异常所导致的疾病的药物。
10.根据权利要求9所述的用途,其特征在于:所述由HDAC活性异常所导致的疾病的药物为由HDAC4、HDAC5、HDAC7、HDAC9活性异常所导致的疾病的药物。
11.根据权利要求8~10所述的用途,其特征在于:所述疾病为细胞增殖疾病、炎症、神经变性疾病、病毒性疾病。
12.一种抑制组蛋白去乙酰化酶活性的药物组合物,其特征在于:它是以权利要求1~7任一项所述的化合物,加上药学上可接受的辅料制备而成的制剂。
13.根据权利要求12所述的一种抑制组蛋白去乙酰化酶活性的药物组合物,其特征在于:所述制剂为口服给药制剂、舌下给药制剂、颊给药制剂、透皮吸收制剂或注射制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910393161.4A CN110256416B (zh) | 2019-05-13 | 2019-05-13 | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910393161.4A CN110256416B (zh) | 2019-05-13 | 2019-05-13 | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110256416A CN110256416A (zh) | 2019-09-20 |
CN110256416B true CN110256416B (zh) | 2024-01-23 |
Family
ID=67913114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910393161.4A Active CN110256416B (zh) | 2019-05-13 | 2019-05-13 | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110256416B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017222951A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
CN109705071A (zh) * | 2017-10-25 | 2019-05-03 | 成都先导药物开发有限公司 | Hdac抑制剂及其制备方法和用途 |
-
2019
- 2019-05-13 CN CN201910393161.4A patent/CN110256416B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017222951A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
CN109705071A (zh) * | 2017-10-25 | 2019-05-03 | 成都先导药物开发有限公司 | Hdac抑制剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN110256416A (zh) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109963844B (zh) | 一类抑制并降解酪氨酸蛋白激酶alk的化合物 | |
CN108314677B (zh) | 一种ezh2抑制剂及其用途 | |
EP3677584A1 (en) | Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity | |
CN116113632A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
EP1870414A1 (en) | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency | |
CN106967005B (zh) | 一种能抑制ido的化合物、其制备方法及其用途 | |
TW201728579A (zh) | 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用 | |
CN103848785A (zh) | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 | |
AU2017203986A1 (en) | Novel furanone derivative | |
CN117362323A (zh) | 一类prmt5抑制剂及其用途 | |
JP2009504692A (ja) | 新規4−アミノ−チエノ[3,2−c]ピリジン−7−カルボン酸アミド | |
Campiani et al. | Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy | |
WO2019120237A1 (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途 | |
CA2747365A1 (fr) | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, leur preparation et leur application en therapeutique | |
CN110256416B (zh) | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 | |
CN111108083B (zh) | 氨基亚甲基环己烷1,3-二酮化合物的用途 | |
CN110229146B (zh) | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 | |
CN114716436A (zh) | Kras g12c突变抑制剂及其用途 | |
KR102629854B1 (ko) | 단백질 키나제 저해제로서 유용한 피리도퀴나졸린 유도체 | |
KR20220033689A (ko) | 히스톤 탈아세틸화효소 억제 활성을 갖는 신규 화합물 및 이의 용도 | |
WO2018059022A1 (zh) | 酪氨酸激酶抑制剂及其应用 | |
KR102674206B1 (ko) | 트랜스글루타미나제-2 활성을 저해하는 신규 화합물 및 이의 용도 | |
CN112110937B (zh) | 一种噻吩并[2,3-d]嘧啶-4(3h)-酮衍生物及其制备方法和用途 | |
RU2798107C2 (ru) | Производные 2,6-диметил-n-((пиридин-4-ил)метил)имидазо[1,2-b]пиридазин-8-амина и 2,5-диметил-n-[(пиридин-4-ил)метил]пиразоло[1,5-a]пиримидин-7-амина для лечения вирусных инфекций | |
CN117756812A (zh) | 一类prmt5抑制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |